For broader context on peptide mechanisms and research applications, explore our Research Library.
Most peptides do one thing well. GHK-Cu does an unusual number of things, and a new 2026 review paper published in Springer Nature’s Systems Microbiology and Biomanufacturing is drawing fresh attention to just how broad its biological footprint actually is.
GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring tripeptide found in human plasma. Its discovery came from an unexpected observation in the 1970s: when plasma from young donors was added to liver cells from older donors, the older cells started producing proteins characteristic of younger tissue. The active compound responsible was identified as GHK, and its copper-bound form GHK-Cu became one of the most studied peptides in regenerative biology. For a deeper breakdown, see our GHK-Cu Research Overview.
What makes GHK-Cu particularly interesting is what happens to it as we age. Plasma levels sit at approximately 200 ng/mL at age 20. By age 60, that figure drops to around 80 ng/mL, a decline that coincides closely with the body’s measurable decrease in regenerative capacity. That correlation has driven decades of research into whether supplementing GHK-Cu can restore some of that biological function.
The 2026 Springer Nature review identifies four primary research areas where GHK-Cu has shown consistent activity in preclinical and clinical models. In tissue repair, it accelerates wound healing through enhanced angiogenesis, collagen deposition, and fibroblast activation. In skin research, clinical trials have shown 25-35% improvements in wrinkle depth and scar appearance, along with measurable increases in skin elasticity and thickness. In hair growth research, a 2022 randomized controlled trial found that a 0.5% GHK-Cu serum increased hair count by 22% at 16 weeks, outperforming 3% minoxidil in the same study. And in gene regulation, genomic research has found GHK-Cu modulates the expression of over 4,000 human genes, including those involved in tissue remodeling, antioxidant defense, anti-inflammatory pathways, and nerve outgrowth.
That last finding is what separates GHK-Cu from most compounds in its category. A peptide that influences gene expression at that scale isn’t operating through a single narrow pathway; it appears to function more like a broad biological reset signal, one that the body naturally produces in response to injury and tissue stress.
GHK-Cu is also among the 14 peptides expected to be reclassified from FDA Category 2 back to Category 1 under the pending reclassification announced by HHS Secretary RFK Jr. in February 2026, which would restore licensed compounding pharmacy access to the compound under physician supervision.
As of 2026, GHK-Cu remains classified as a research compound. The evidence base from preclinical and clinical studies is substantial, but large-scale randomized controlled trials with long follow-up periods are still needed to establish definitive clinical protocols.
Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of New Gene Data — PMC / NCBI